A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants
ConditionHV
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorShanghai Argo Biopharmaceutical Co., Ltd.
About this trial
A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants
Eligibility criteria
Qualifiers
Must have given written informed consent and be able to comply with all study requirements
Males or females aged 18 to 60 years old, inclusive, at the time of informed consent.
Body mass index (BMI) ≥18 and ≤32 kg/m2 and body weight ≥50 kg Female participants must be non-pregnant
Male participants with female partners of child-bearing potential must agree to use acceptable methods of contraception from screening until 48 weeks following administration of the study drug
Disqualifiers
Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that
Any skin condition and/or tattoo that may interfere with the evaluation of safety at the injection site
Hospitalization for any reason within 60 days prior to screening.
Presence of carcinoma and history of carcinoma
Trial design
Treatments tested in this trial
- BW-20805
- BW-20805
- BW-20805-2
Treatment groups
24 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov